Dublin, Calif. – June 1, 2020 – Azure Biosystems is excited to announce a new partnership with CerFlux, an Alabama-based company specializing in personalized medicine technology. The Azure Sapphire Biomolecular Imager is an important part of the imaging technology currently being used at CerFlux as we continue our work on our National Institutes of Health / National Cancer Institute and Breast Cancer Research Foundation of Alabama grant projects.
Azure is excited to support CerFlux in their mission to study in vivo and ex vivo cancer models. Click here for a full list of application notes, videos and more on this novel use of the Azure Sapphire Biomolecular Imager.
Stay up to date on updates from Azure Biosystems by following our LinkedIn page.
Pictured: Two scientists at CerFlux working with the Azure Sapphire Biomolecular Imager
About Azure Biosystems
Azure Biosystems Inc. is an innovative life science platform company that designs, develops and markets state-of-the-art instruments, including Sapphire Biomolecular Imaging Systems, and Azure Imaging Systems. By designing instruments that combine quantitative detection, enhanced flexibility, and streamlined workflows, we enable scientists to quickly and confidently advance their studies using the workflows that work best for them. With an experienced team that has decades of experience developing 2nd and 3rd generation imaging systems for the life science market, we create innovative platforms that set the definition of industry standards.
For additional information, please see https://www.azurebiosystems.com.